Floatz logo

Ltld

Invasive Ductal Breast Cancer

UMC UtrechtPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Invasive Ductal Breast Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
GBG Forschungs GmbH
Phase 3BBB
Cyclophosphamide
UMC Utrecht
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
RenJi Hospital
Phase 3BB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
GBG Forschungs GmbH
Phase 3BB
TRASTUZUMAB
GBG Forschungs GmbH
Phase 3BB

View all 11 →

Same molecule, other indications

Ltld is also rated in:

breast carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
breast cancerDormant
C
Indicative ·
39 / 100
View asset →
metastatic malignant neoplasmDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →